Profile data is unavailable for this security.
About the company
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
- Revenue in USD (TTM)0.00
- Net income in USD20.86m
- Incorporated2011
- Employees15.00
- LocationOramed Pharmaceuticals Inc1185 AVENUE OF THE AMERICAS, 3RD FLOORNEW YORK 10036United StatesUSA
- Phone+1 (646) 844-1164
- Fax+1 (845) 818-3588
- Websitehttps://oramed.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | 145.67m | -89.91m | 92.15m | 325.00 | -- | -- | -- | 0.6326 | -0.8356 | -0.8356 | 1.17 | -1.06 | 0.5692 | 1.62 | 4.15 | 448,209.20 | -35.14 | -53.02 | -45.50 | -65.85 | 96.04 | 97.18 | -61.72 | -125.15 | 3.56 | -7.37 | 2.00 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Ikena Oncology Inc | 1.84m | -66.71m | 93.41m | 18.00 | -- | 0.5776 | -- | 50.66 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Coya Therapeutics Inc | 9.55m | -10.10m | 94.68m | 8.00 | -- | 2.69 | -- | 9.91 | -0.7726 | -0.7726 | 0.7589 | 2.32 | 0.3512 | -- | -- | 1,194,290.00 | -37.13 | -- | -40.92 | -- | -- | -- | -105.71 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -57.72m | 95.03m | 72.00 | -- | 0.5302 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| bluebird bio Inc | 45.69m | -302.96m | 95.41m | 375.00 | -- | 0.7268 | -- | 2.09 | -2.44 | -2.44 | 0.3452 | 0.677 | 0.069 | 3.28 | -- | 121,837.30 | -45.76 | -34.75 | -66.24 | -40.84 | -22.60 | -124.35 | -663.09 | -5,770.41 | 0.8219 | -28.60 | 0.615 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
| Clearside Biomedical Inc | 7.52m | -33.46m | 95.67m | 30.00 | -- | -- | -- | 12.72 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -88.51m | 98.35m | 20.00 | -- | -- | -- | -- | -2.52 | -2.52 | 0.00 | -0.2208 | 0.00 | -- | -- | 0.00 | -77.89 | -38.44 | -81.83 | -39.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.16 | -- | -- | -- |
| Metagenomi Inc | 55.93m | -75.00m | 98.53m | 228.00 | -- | 0.3657 | -- | 1.76 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 99.06m | 22.00 | -- | 1.16 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 100.70m | 15.00 | 4.94 | 0.5668 | 4.80 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Werewolf Therapeutics Inc | 9.28m | -53.73m | 104.89m | 45.00 | -- | 1.01 | -- | 11.30 | -1.35 | -1.35 | 0.236 | 2.38 | 0.0548 | -- | 2.48 | 197,510.60 | -31.70 | -- | -34.39 | -- | -- | -- | -578.80 | -- | -- | -- | 0.1948 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Sagimet Biosciences Inc | 2.00m | -29.25m | 105.60m | 10.00 | -- | 0.5711 | -- | 52.80 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -86.76m | 105.61m | 20.00 | -- | 1.72 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -60.34m | 108.67m | 54.00 | -- | 1.65 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 78.00k | -42.47m | 109.39m | 23.00 | -- | -- | -- | 1,402.48 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Oramed Pharmaceuticals Inc's reporting currency: US Dollar USD
12.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Murchinson Ltd.as of 30 Jun 2024 | 1.70m | 4.17% |
| BML Capital Management LLCas of 30 Jun 2024 | 1.35m | 3.31% |
| Boothbay Fund Management LLCas of 30 Jun 2024 | 825.00k | 2.02% |
| Rathbones Investment Management Ltd.as of 30 Jun 2024 | 289.80k | 0.71% |
| Two Sigma Advisers LPas of 30 Jun 2024 | 259.10k | 0.64% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 230.80k | 0.57% |
| Two Sigma Investments LPas of 30 Jun 2024 | 150.37k | 0.37% |
| Merrill Lynch International (Investment Management)as of 30 Jun 2024 | 144.51k | 0.35% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 125.83k | 0.31% |
| KSM Mutual Funds Ltd.as of 30 Jun 2024 | 124.84k | 0.31% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
